Business
GSK appoints CEO designate
GSK appoints CEO designate.
About this update from Gsk Plc
[{"type":"text","content":"\n\nIssued: 29 September 2025, London UK\n \nLuke Miels appointed CEO designate for GSK\n \n· Luke to assume full responsibilities as CEO from 1st January 2026\n \n \n\nGSK plc (LSE/NYSE: GSK) today announces that Luke Miels is appointed CEO Designate, GSK. He will assume full responsibilities as CEO and join the Board on 1st January 2026.\n \nLuke joined GSK in 2017 and is currently Chief Commercial Officer, with world-wide responsibility for medicines and vaccines1. He has been instrumental in building GSK's specialty medicines portfolio, notably in oncology and respiratory. Luke is a highly respected, experienced global biopharma leader, having worked at senior levels in the US, Europe and Asia, at AstraZeneca, Roche and Sanofi-Aventis, prior to joining GSK. This experience, and significant contribution to GSK, mean he is exceptionally well-qualified to lead the company, and to deliver the patient and shareholder value inherent in the company's future ambitions.\n \nLuke will succeed current CEO, Dame Emma Walmsley. Since her appointment as CEO, Emma has delivered a comprehensive step-change in GSK's operating performance, portfolio and pipeline, prioritising the development of specialty medicines and vaccines, and delivering multiple major new products. R&D has been reinvigorated during her tenure, with 15 major pipeline opportunities now set to launch in 2025-31. At the same time, GSK's balance sheet has been strengthened, and following the successful demerger of consumer healthcare, a new industry-leading company, Haleon, has been created.\n \nGSK is now performing to a new standard, with clear outlooks for long-term growth including total sales expectations of more than £40 billion by 20312 and 2026 marks the start of a pivotal new phase for GSK to deliver these outlooks.\n \nSir Jonathan Symonds CBE, Chair of GSK, said: \"On behalf of the Board, I want to thank Emma and acknowledge her outstanding leadership in delivering a strategic transformation of GSK, including the successful demerger of Haleon. GSK today is necessarily very different to the company she was appointed to nine years ago and has a bright and ambitious future. The company is performing to a new, more competitive standard, with performance anchored in a stronger portfolio balanced across specialty m...